News

CFDA announced drug clinical trial agency with qualification (No. 57, 2017)

2017-05-23

On May 16th, 2017, CFDA announced drug clinical trial agency with qualification (No.7), No. 57, 2017). It is pointed out in the announcement that according to Drug Control Law of P.R.C. and Measures of Drug Clinical Trial Agency Qualification Accreditation (on trial), after data review and on-site inspection, including International Hospital of Peking University, 149 medical agencies were recognized as drug clinical trial agencies, and granted them with “ Certificate of Drug Clinical Trial Agency”.

Original link

http://www.sda.gov.cn/WS01/CL0069/172689.html

Previous article

Can we win the battle with “Super Bacteria”?

Next article

Ministry of Science and Technology print and distribute biotechnology innovative plan of “the 13th five year plan”

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China